PRESS RELEASES

Year
November 19 | 2018
FLX Bio to Present at Evercore ISI HealthCONx Conference
November 08 | 2018
FLX Bio Highlights Phase 1 Data for FLX475 at SITC 2018
November 05 | 2018
FLX Bio Announces Clinical Trial Collaboration Agreement With Merck for Ongoing Phase 1/2 Study of FLX475
October 03 | 2018
FierceBiotech Names FLX Bio as One of its “Fierce 15” Biotech Companies of 2018
September 27 | 2018
FLX Bio Announces First Patient Dosed With FLX475, a Best-in-Class CCR4 Inhibitor for the Treatment of Multiple Cancers
August 08 | 2018
FLX Bio to Present at the 2018 Wedbush PacGrow Healthcare Conference
June 01 | 2018
FLX Bio to Present at the Jefferies Global Healthcare Conference
April 12 | 2018
FLX Bio to Highlight New Preclinical Data from CCR4 and USP7 Programs at the American Academy for Cancer Research Annual Meeting
February 12 | 2018
FLX Bio to Present at RBC Capital Markets 2018 Global Healthcare Conference
February 05 | 2018
FLX Bio Adds Distinguished Biopharma Industry Leader Michael Giordano, M.D., to Board of Directors
January 03 | 2018
FLX Bio Appoints Dirk G. Brockstedt, Ph.D., as Senior Vice President of Biology